|Chemical and physical data|
|Molar mass||500.34 g·mol−1|
|3D model (JSmol)|
PF-05089771 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic. As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|